304 related articles for article (PubMed ID: 31307411)
1. Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer.
Gong W; Liu Y; Seidl C; Diamandis EP; Kiechle M; Drecoll E; Kotzsch M; Magdolen V; Dorn J
BMC Cancer; 2019 Jul; 19(1):696. PubMed ID: 31307411
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer.
Gong W; Liu Y; Diamandis EP; Kiechle M; Bronger H; Dorn J; Dreyer T; Magdolen V
J Ovarian Res; 2020 Oct; 13(1):125. PubMed ID: 33087135
[TBL] [Abstract][Full Text] [Related]
3. Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients.
Gong W; Liu Y; Seidl C; Dreyer T; Drecoll E; Kotzsch M; Bronger H; Dorn J; Magdolen V
PLoS One; 2019; 14(2):e0212968. PubMed ID: 30811511
[TBL] [Abstract][Full Text] [Related]
4. Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis.
Dettmar L; Ahmed N; Kotzsch M; Diersch S; Napieralski R; Darmoul D; Schmitt M; Weichert W; Kiechle M; Dorn J; Magdolen V
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1109-1118. PubMed ID: 29546479
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer.
Geng X; Liu Y; Diersch S; Kotzsch M; Grill S; Weichert W; Kiechle M; Magdolen V; Dorn J
PLoS One; 2017; 12(11):e0186847. PubMed ID: 29095848
[TBL] [Abstract][Full Text] [Related]
6. Uncovering the clinical impact of kallikrein-related peptidase 5 (KLK5) mRNA expression in the colorectal adenoma-carcinoma sequence.
Papachristopoulou G; Malachias A; Devetzi M; Kamouza E; Scorilas A; Xynopoulos D; Talieri M
Clin Chem Lab Med; 2019 Jul; 57(8):1251-1260. PubMed ID: 30759066
[TBL] [Abstract][Full Text] [Related]
7. Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome.
Dorn J; Yassouridis A; Walch A; Diamandis EP; Schmitt M; Kiechle M; Wang P; Drecoll E; Schmalfeldt B; Loessner D; Kotzsch M; Magdolen V
Am J Cancer Res; 2016; 6(1):61-70. PubMed ID: 27073723
[TBL] [Abstract][Full Text] [Related]
8. Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer.
Yousef GM; Scorilas A; Kyriakopoulou LG; Rendl L; Diamandis M; Ponzone R; Biglia N; Giai M; Roagna R; Sismondi P; Diamandis EP
Clin Chem; 2002 Aug; 48(8):1241-50. PubMed ID: 12142380
[TBL] [Abstract][Full Text] [Related]
9. Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis.
Diamandis EP; Borgoño CA; Scorilas A; Yousef GM; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M
Tumour Biol; 2003; 24(6):299-309. PubMed ID: 15004490
[TBL] [Abstract][Full Text] [Related]
10. Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival.
Dorn J; Magdolen V; Gkazepis A; Gerte T; Harlozinska A; Sedlaczek P; Diamandis EP; Schuster T; Harbeck N; Kiechle M; Schmitt M
Ann Oncol; 2011 Aug; 22(8):1783-90. PubMed ID: 21273346
[TBL] [Abstract][Full Text] [Related]
11. Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer.
Zhao S; Dorn J; Napieralski R; Walch A; Diersch S; Kotzsch M; Ahmed N; Hooper JD; Kiechle M; Schmitt M; Magdolen V
Biol Chem; 2017 Jun; 398(7):765-773. PubMed ID: 27935848
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer.
Ahmed N; Dorn J; Napieralski R; Drecoll E; Kotzsch M; Goettig P; Zein E; Avril S; Kiechle M; Diamandis EP; Schmitt M; Magdolen V
Biol Chem; 2016 Dec; 397(12):1265-1276. PubMed ID: 27483364
[TBL] [Abstract][Full Text] [Related]
13. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer.
Kim H; Scorilas A; Katsaros D; Yousef GM; Massobrio M; Fracchioli S; Piccinno R; Gordini G; Diamandis EP
Br J Cancer; 2001 Mar; 84(5):643-50. PubMed ID: 11237385
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of GPNMB predicts an unfavorable outcome of epithelial ovarian cancer.
Ma RQ; Tang ZJ; Ye X; Cheng HY; Sun KK; Chang XH; Cui H
Arch Gynecol Obstet; 2018 May; 297(5):1235-1244. PubMed ID: 29428978
[TBL] [Abstract][Full Text] [Related]
15. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
16. [Expression of lnc-MyD88 and its relationship with the prognosis of patients with epithelial ovarian cancer].
Zhu Y; Huang JM; Zhang GN; Li JM; Huang J
Zhonghua Fu Chan Ke Za Zhi; 2022 Feb; 57(2):117-124. PubMed ID: 35184472
[No Abstract] [Full Text] [Related]
17. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
[TBL] [Abstract][Full Text] [Related]
18. Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients.
Liu P; Wang Y; Tong L; Xu Y; Zhang W; Guo Z; Ni H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1163-71. PubMed ID: 26542279
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma.
Luo LY; Katsaros D; Scorilas A; Fracchioli S; Piccinno R; Rigault de la Longrais IA; Howarth DJ; Diamandis EP
Clin Cancer Res; 2001 Aug; 7(8):2372-9. PubMed ID: 11489815
[TBL] [Abstract][Full Text] [Related]
20. Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers.
Dong Y; Kaushal A; Brattsand M; Nicklin J; Clements JA
Clin Cancer Res; 2003 May; 9(5):1710-20. PubMed ID: 12738725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
